Judge questions Hegseth testosterone policy
Analysis based on 7 articles · First reported Jul 22, 2026 · Last updated Jul 23, 2026
The event is unlikely to have significant direct market impact. However, it may affect sentiment around defense contractor stocks if policy changes are perceived as disruptive to military readiness.
U.S. District Judge Ana Reyes questioned the differences between Defense Secretary Pete Hegseth's new testosterone replacement therapy (TRT) screening program for troops and hormone treatment for transgender men in the military, in the context of an ongoing lawsuit against President Donald Trump's ban on transgender troops. Reyes ordered both parties to address similarities and differences in administering TRT. Hegseth announced the screening program a week earlier, calling it necessary for troops to operate at their best. The Trump administration's transgender military ban remains in effect as litigation continues.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard